Halozyme Therapeutics (HALO) – Analysts’ Weekly Ratings Updates

Halozyme Therapeutics (NASDAQ: HALO) recently received a number of ratings updates from brokerages and research firms:

• 2/3/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by analysts at Benchmark Co..
• 1/31/2026 – Halozyme Therapeutics was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 1/29/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 1/26/2026 – Halozyme Therapeutics was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 1/8/2026 – Halozyme Therapeutics had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Halozyme Therapeutics was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 12/22/2025 – Halozyme Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – Halozyme Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
• 12/15/2025 – Halozyme Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Halozyme Therapeutics was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the completion of the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $48,844,913.48. The trade was a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 41,398 shares of company stock worth $2,861,352 in the last ninety days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.